ARTL

Business Context and Reporting Period

Company: Artelo Biosciences, Inc. (ARTL)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system (ECS). The company has no approved products and generates no revenue. Its pipeline includes three primary candidates: ART27.13 (cancer-related anorexia), ART26.12 (chemotherapy-induced peripheral neuropathy and oncology), and ART12.11 (anxiety disorders).

Key Financial Metrics

Note: The filing text does not provide specific gross margin or operating margin data as the company has no revenue.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $3.1 million (31%) to $12.9 million, driven by higher general and administrative expenses (up $1.9 million) and significant non-operating losses related to debt extinguishment ($1.2 million).
• Liquidity Deterioration: Cash and cash equivalents declined by 74% to $0.6 million. Working capital shifted from a positive $0.8 million in 2024 to a negative $3.3 million in 2025.
• Debt Issuance: The company issued convertible notes totaling approximately $0.9 million in 2025, resulting in a $0.6 million balance at year-end, compared to zero in 2024.
• Financing Activity: Net cash provided by financing activities surged to $6.9 million in 2025 (from $0.1 million in 2024) due to multiple equity offerings and convertible note issuances.

Guidance, Outlook, Risks, and Unusual Items

Going Concern Warning

Management has raised substantial doubt about the company's ability to continue as a going concern. With only $0.6 million in cash and a negative working capital position, the company requires additional financing to fund operations for the next 12 months. There is no assurance that such financing will be available on acceptable terms.

Clinical Progress

• ART27.13: Interim Phase 2a results (announced Sept 2025) showed a mean weight gain of 6.38% in treated patients versus a 5.42% loss in placebo for cancer anorexia. Safety profile remained favorable.
• ART26.12: Completed Phase 1 Single Ascending Dose study in healthy volunteers with favorable safety and tolerability results.

Key Risks

• Nasdaq Delisting: The company received a delisting determination from Nasdaq in November 2025 due to failure to meet minimum stockholders' equity requirements ($2.5 million). An appeal was filed, and a hearing panel granted an extension until March 30, 2026, to resolve the deficiency.
• Capital Requirements: Continued reliance on equity or debt financing creates dilution risk and potential covenant restrictions.
• Regulatory & IP: Risks associated with clinical trial outcomes, FDA approval timelines, and maintaining patent licenses with third parties (NEOMED and Stony Brook University).

Unusual Items

The 2025 financials include a loss on extinguishment of debt of $1.2 million (including $0.3 million related party) resulting from the restructuring of convertible notes in October 2025. Additionally, the company adopted ASU 2023-08 for crypto assets, recognizing a $62,000 loss on the sale of Solana tokens.

Investor Verification Checklist

• Capital Runway: Verify the status of the January 2026 Equity Line agreement with Square Gate Capital ($25 million commitment) and whether funds have been drawn to address the going concern warning.
• Nasdaq Compliance: Monitor the March 30, 2026 deadline for resolving the stockholders' equity deficiency to avoid delisting.
• Clinical Trial Enrollment: Confirm the pace of enrollment for the ART27.13 Phase 2a trial (32 enrolled as of Dec 31, 2025) and the timeline for final data readout.
• Debt Obligations: Review the terms of the outstanding convertible notes ($0.6 million) and the potential for further dilution upon conversion or maturity.
• UK Tax Credits: Assess the impact of UK legislative changes on R&D tax credits, which may reduce the value of credits and delay payments.